ArticleScientific reports2018
Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Enhancing in vivo cell and tissue targeting by modulation of polymer nanoparticles and macrophage decoys.Nature communications · 2024Article
- Priming agents transiently reduce the clearance of cell-free DNA to improve liquid biopsies.Science (New York, N.Y.) · 2024Article
- Reducing off-target drug accumulation by exploiting a type-III interferon response.Journal of controlled release : official journal of the Controlled Release Society · 2023Article
- Review
- Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery.Pharmaceutics · 2023Review
- Advanced strategies to evade the mononuclear phagocyte system clearance of nanomaterials.Exploration (Beijing, China) · 2023Review
- Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs.Nature reviews. Materials · 2023Review
- Radiation nanosensitizers in cancer therapy-From preclinical discoveries to the outcomes of early clinical trials.Bioengineering & translational medicine · 2022Review
- Delivering the power of nanomedicine to patients today.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Impacts of Intralipid on Nanodrug Abraxane Therapy and on the Innate Immune System.Scientific reports · 2020Article
- High-throughput quantitative microscopy-based half-life measurements of intravenously injected agents.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Nanoscale Chemical Imaging of Individual, Chemotherapeutic Cytarabine-loaded Liposomal Nanocarriers.Nano research · 2019Article
- Advancing Medical Applications of Cancer Nanotechnology: Highlighting Two Decades of the NCI'S Nanotechnology Characterization Laboratory Service to the Research Community.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many therapeutic agents offer a low useful dose (dose responsible for efficacy)/useless dose (dose eliminated or responsible for toxicity) ratio, mainly due to the fact that therapeutic agents must ensure in one single object all the functions required to deliver the treatment, which leads to compromises in their physico-chemical design. Here we introduce the concept of priming the body to receive the treatment by uncorrelating these functions into two distinct objects sequentially administered: a nanoprimer occupying transiently the main pathway responsible for therapeutic agent limited benefit/risk ratio followed by the therapeutic agent. The concept was evaluated for different nature of therapeutic agents: For nanomedicines we designed a liposomal nanoprimer presenting preferential hepatic accumulation without sign of acute toxicity. This nanoprimer was able to increase the blood bioavailability of nanomedicine correlated with a lower hepatic accumulation. Finally this nanoprimer markedly enhanced anti-tumor efficacy of irinotecan loaded liposomes in the HT-29 tumor model when compared to the nanomedicine alone. Then, for small molecules we demonstrated the ability of a cytochrome inhibitor loaded nanoprimer to increase efficacy of docetaxel treatment. These results shown that specific nanoprimers could be designed for each family of therapeutic agents to answer to their specific needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.